# A Study of MRG002 in the Treatment of HER2-positive Unresectable, Locally Advanced or Metastatic Biliary Tract Cancer

> **NCT04837508** · PHASE2 · UNKNOWN · sponsor: **Shanghai Miracogen Inc.** · enrollment: 86 (estimated)

## Conditions studied

- Advanced or Metastatic Biliary Tract Cancer

## Interventions

- **DRUG:** MRG002

## Key facts

- **NCT ID:** NCT04837508
- **Lead sponsor:** Shanghai Miracogen Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2021-06-07
- **Primary completion:** 2022-12
- **Final completion:** 2023-08
- **Target enrollment:** 86 (ESTIMATED)
- **Last updated:** 2021-12-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04837508

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04837508, "A Study of MRG002 in the Treatment of HER2-positive Unresectable, Locally Advanced or Metastatic Biliary Tract Cancer". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT04837508. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*